Perspectives on adherence and persistence with oral medications for cancer treatment

Journal of Oncology Practice

Volumn 7, Issue 1, 2011, Pages 65-67

  Hohneker, By John ^a   Shah Mehta, Shilpa ^a   Brandt, Patricia S ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; IMATINIB; LETROZOLE; TAMOXIFEN;

BREAST CANCER; CANCER HORMONE THERAPY; CHRONIC MYELOID LEUKEMIA; COLON CANCER; GASTROINTESTINAL STROMAL TUMOR; HUMAN; NEOPLASM; PATIENT COMPLIANCE; REVIEW;

EID: 79955698843     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2010.000076     Document Type: Review

References (30)

1. Cramer JA, Roy A, Burrell A, et al: Medication compliance and persistence: Terminology and definitions. Value Health 11:44-47, 2008 (Pubitemid 351160875)
2. Yeaw J, Benner JS, Walt JG, et al: Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15:728-740, 2009
3. Weingart SN, Brown E, Bach PB, et al: NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw 6:S1-S14, 2008 (suppl 3) (Pubitemid 351497279)
4. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003 (Pubitemid 36302244)
5. Coates AS, Keshaviah A, Thürlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine- responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492, 2007 (Pubitemid 350002953)
6. Baum M, Buzdar A, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98: 1802-1810, 2003 (Pubitemid 37310221)
7. Ziller V, Kalder M, Albert US, et al: Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20:431-436, 2009
8. Partridge AH, LaFountain A, Mayer E, et al: Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26:556-562, 2008 (Pubitemid 351264348)
9. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542, 1996 (Pubitemid 26374506)
10. Barron TI, Connolly R, Bennett K, et al: Early discontinuation of tamoxifen: A lesson for oncologists. Cancer 109:832-839, 2007 (Pubitemid 46333524)
11. Fink AK, Gurwitz J, Rakowski W, et al: Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22:3309-3315, 2004 (Pubitemid 41103687)
12. Lash TL, Fox MP, Westrup JL, et al: Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215-220, 2006 (Pubitemid 44268270)
13. Partridge AH, Wang PS, Winer EP, et al: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602-606, 2003 (Pubitemid 46621892)
14. Stricker CT, Palmer SC, DeMichele A, et al: Understanding premature discontinuation of aromatase inhibitor (AI) therapy in postmenopausal breast cancer survivors. J Clin Oncol 28:465s, 2010 (suppl; abstr 6073)
15. Hershman DL, Kushi LH, Shao T, et al: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120-4128, 2010
16. Charlson JA, Hedin T, Sparapani R, et al: Early discontinuation of tamoxifen and aromatase inhibitors (AIs) by postmenopausal women with early-stage breast cancer. J Clin Oncol 28:73s, 2010 (suppl; abstr 524)
17. Rey-Herin D, Bouhnik AD, Cortaredona S, et al: Low adherence to long-term adjuvant endocrine therapy in breast cancer women age 40 or younger. J Clin Oncol 28:102s, 2010 (suppl; abstr 643)
18. Partridge AH, Archer L, Kornblith AB, et al: Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: Adherence companion study 60104. J Clin Oncol 28:2418-2422, 2010
19. Mayer EL, Partridge AH, Harris LN, et al: Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat 117:615-623, 2009
20. Roth S, Simons S, Arjukese A, et al: Adherence in cancer patients receiving oral capecitabine. Value Health 9:A295, 2006
21. Tsang J, Rudychev I, Pescatore SL, et al: Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). J Clin Oncol 24: 330s, 2006 (suppl; abstr 6119)
22. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-15, 1981 (Pubitemid 11212891)
23. Doti C, Stemmelin G, Shanley C, et al: Cytogenetic response in relation to the adherence to treatment with imatinib mesylate: A case control study. Blood 11: 4553, 2007
24. Noens L, van Lierde MA, De Bock R, et al: Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood 113:5401-5411, 2009
25. Wu EQ, Johnson S, Beaulieu N, et al: Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 26:61-69, 2010
26. McCowan C, Shearer J, Donnan PT, et al: Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99:1763-1768, 2008
27. Bazeos A, Khorashad J, Mahon F-X, et al: Long term adherence to imatinib therapy is the critical factor for achieving molecular responses in chronic myeloid leukemia patients. Blood 114:3290, 2009
28. Partridge AH, Avorn J, Wang PS, et al: Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94:652-661, 2002 (Pubitemid 34552485)
29. St. Charles M, Bollu V, Hornyak B, et al: Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. Blood 114:2209, 2009
30. Osterberg L, Blaschke T: Adherence to medication. N Engl J Med 353:487-497, 2005 (Pubitemid 41127293)